These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 23442043)

  • 1. Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib.
    Derenzini E; Younes A
    Expert Opin Investig Drugs; 2013 Jun; 22(6):775-85. PubMed ID: 23442043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The development, safety and efficacy of pacritinib for the treatment of myelofibrosis.
    Jain T; Mesa R
    Expert Rev Anticancer Ther; 2016 Nov; 16(11):1101-1108. PubMed ID: 27598824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes.
    Younes A; Romaguera J; Fanale M; McLaughlin P; Hagemeister F; Copeland A; Neelapu S; Kwak L; Shah J; de Castro Faria S; Hart S; Wood J; Jayaraman R; Ethirajulu K; Zhu J
    J Clin Oncol; 2012 Nov; 30(33):4161-7. PubMed ID: 22965964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma.
    William AD; Lee AC; Blanchard S; Poulsen A; Teo EL; Nagaraj H; Tan E; Chen D; Williams M; Sun ET; Goh KC; Ong WC; Goh SK; Hart S; Jayaraman R; Pasha MK; Ethirajulu K; Wood JM; Dymock BW
    J Med Chem; 2011 Jul; 54(13):4638-58. PubMed ID: 21604762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pacritinib to treat myelofibrosis patients with thrombocytopenia.
    Tremblay D; Mascarenhas J
    Expert Rev Hematol; 2018 Sep; 11(9):707-714. PubMed ID: 30001163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comprehensive review of pacritinib in myelofibrosis.
    Verstovsek S; Komrokji RS
    Future Oncol; 2015; 11(20):2819-30. PubMed ID: 26367195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies.
    Hart S; Goh KC; Novotny-Diermayr V; Hu CY; Hentze H; Tan YC; Madan B; Amalini C; Loh YK; Ong LC; William AD; Lee A; Poulsen A; Jayaraman R; Ong KH; Ethirajulu K; Dymock BW; Wood JW
    Leukemia; 2011 Nov; 25(11):1751-9. PubMed ID: 21691275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines.
    Yang EG; Mustafa N; Tan EC; Poulsen A; Ramanujulu PM; Chng WJ; Yen JJ; Dymock BW
    J Med Chem; 2016 Sep; 59(18):8233-62. PubMed ID: 27541357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JAK2 inhibitors in the treatment of myeloproliferative neoplasms.
    Tibes R; Bogenberger JM; Geyer HL; Mesa RA
    Expert Opin Investig Drugs; 2012 Dec; 21(12):1755-74. PubMed ID: 22991927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies.
    Verstovsek S; Odenike O; Singer JW; Granston T; Al-Fayoumi S; Deeg HJ
    J Hematol Oncol; 2016 Dec; 9(1):137. PubMed ID: 27931243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deregulated JAK/STAT signalling in lymphomagenesis, and its implications for the development of new targeted therapies.
    Scott LM; Gandhi MK
    Blood Rev; 2015 Nov; 29(6):405-15. PubMed ID: 26123794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-based design of oxygen-linked macrocyclic kinase inhibitors: discovery of SB1518 and SB1578, potent inhibitors of Janus kinase 2 (JAK2) and Fms-like tyrosine kinase-3 (FLT3).
    Poulsen A; William A; Blanchard S; Lee A; Nagaraj H; Wang H; Teo E; Tan E; Goh KC; Dymock B
    J Comput Aided Mol Des; 2012 Apr; 26(4):437-50. PubMed ID: 22527961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The JAK2/STAT3 inhibitor pacritinib effectively inhibits patient-derived GBM brain tumor initiating cells in vitro and when used in combination with temozolomide increases survival in an orthotopic xenograft model.
    Jensen KV; Cseh O; Aman A; Weiss S; Luchman HA
    PLoS One; 2017; 12(12):e0189670. PubMed ID: 29253028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pacritinib and its use in the treatment of patients with myelofibrosis who have thrombocytopenia.
    Diaz AE; Mesa RA
    Future Oncol; 2018 Apr; 14(9):797-807. PubMed ID: 29235894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JAK/STAT signaling in hematological malignancies.
    Vainchenker W; Constantinescu SN
    Oncogene; 2013 May; 32(21):2601-13. PubMed ID: 22869151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures.
    Singer JW; Al-Fayoumi S; Taylor J; Velichko S; O'Mahony A
    PLoS One; 2019; 14(9):e0222944. PubMed ID: 31560729
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.
    Kleppe M; Kwak M; Koppikar P; Riester M; Keller M; Bastian L; Hricik T; Bhagwat N; McKenney AS; Papalexi E; Abdel-Wahab O; Rampal R; Marubayashi S; Chen JJ; Romanet V; Fridman JS; Bromberg J; Teruya-Feldstein J; Murakami M; Radimerski T; Michor F; Fan R; Levine RL
    Cancer Discov; 2015 Mar; 5(3):316-31. PubMed ID: 25572172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pacritinib: a new agent for the management of myelofibrosis?
    Beauverd Y; McLornan DP; Harrison CN
    Expert Opin Pharmacother; 2015; 16(15):2381-90. PubMed ID: 26389774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced synergy of pacritinib with temsirolimus and sunitinib in preclinical renal cell carcinoma model by targeting JAK2/STAT pathway.
    Mao F; Gao L; Liu L; Tang Y
    J Chemother; 2024 May; 36(3):238-248. PubMed ID: 37916436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies on the anti-psoriasis effects and its mechanism of a dual JAK2/FLT3 inhibitor flonoltinib maleate.
    Zhu J; Yang T; Tang M; Yang Z; Pei H; Ye H; Tang Y; Cheng Z; Lin P; Chen L
    Biomed Pharmacother; 2021 May; 137():111373. PubMed ID: 33761599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.